217 related articles for article (PubMed ID: 26432873)
1. Therapeutic potential of soluble guanylate cyclase modulators in neonatal chronic lung disease.
Wagenaar GT; Hiemstra PS; Gosens R
Am J Physiol Lung Cell Mol Physiol; 2015 Nov; 309(10):L1037-40. PubMed ID: 26432873
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
4. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase modulates alveolarization in the newborn lung.
Bachiller PR; Cornog KH; Kato R; Buys ES; Roberts JD
Am J Physiol Lung Cell Mol Physiol; 2013 Oct; 305(8):L569-81. PubMed ID: 23934926
[TBL] [Abstract][Full Text] [Related]
7. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
[TBL] [Abstract][Full Text] [Related]
9. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
11. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Sandner P; Stasch JP
Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
13. The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease.
Glynos C; Dupont LL; Vassilakopoulos T; Papapetropoulos A; Brouckaert P; Giannis A; Joos GF; Bracke KR; Brusselle GG
Am J Respir Crit Care Med; 2013 Oct; 188(7):789-99. PubMed ID: 23841447
[TBL] [Abstract][Full Text] [Related]
14. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
15. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
17. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857
[TBL] [Abstract][Full Text] [Related]
19. An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling.
Ghosh A; Koziol-White CJ; Jester WF; Erzurum SC; Asosingh K; Panettieri RA; Stuehr DJ
Redox Biol; 2021 Feb; 39():101832. PubMed ID: 33360351
[TBL] [Abstract][Full Text] [Related]
20. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
